Letter: PCSK9 inhibitor for liver transplant patients during the post-statin era?

Jiamei Wang^{1

2}, Jia Wu³, Zhiqing He^{1

2}, Haiguang Xin⁴

Affiliations

¹ Department of Cardiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
² Shanghai Cardiovascular Institute of Integrative Medicine, Shanghai, China.
³ Department of Health Management Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
⁴ Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Comment

Jiamei Wang et al. Aliment Pharmacol Ther. 2023 Jan.

. 2023 Jan;57(1):185-186.

doi: 10.1111/apt.17258.

Jiamei Wang^{1

2}, Jia Wu³, Zhiqing He^{1

2}, Haiguang Xin⁴

¹ Department of Cardiology, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
² Shanghai Cardiovascular Institute of Integrative Medicine, Shanghai, China.
³ Department of Health Management Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
⁴ Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

No abstract available

Comment in

Letter: PCSK9 inhibitor for liver transplant patients during the post-statin era? Authors' reply.
Becchetti C, Dirchwolf M, Berzigotti A, Bosch J. Becchetti C, et al. Aliment Pharmacol Ther. 2023 Jan;57(1):187-188. doi: 10.1111/apt.17295. Aliment Pharmacol Ther. 2023. PMID: 36480715 No abstract available.

Use of statins after liver transplantation is associated with improved survival: results of a nationwide study.
Becchetti C, Dirchwolf M, Schropp J, Magini G, Müllhaupt B, Immer F, Dufour JF, Banz V, Berzigotti A, Bosch J; Swiss Transplant Cohort Study. Becchetti C, et al. Aliment Pharmacol Ther. 2022 Oct;56(7):1194-1204. doi: 10.1111/apt.17192. Epub 2022 Aug 18. Aliment Pharmacol Ther. 2022. PMID: 35979872 Free PMC article.

1. Becchetti C, Dirchwolf M, Schropp J, Magini G, Müllhaupt B, Immer F, et al. Use of statins after liver transplantation is associated with improved survival: results of a nationwide study. Aliment Pharmacol Ther. 2022;56(7):1194-204.
1. Lee O, Rhu J, Choi G-S, et al. Impact of statins on hepatocellular carcinoma recurrence after living-donor liver transplantation. Ann Transplant. 2022;27:e935604-1-9.
1. Patel SS, Rodriguez VA, Siddiqui MB, Faridnia M, Lin F-P, Chandrakumaran A, et al. The impact of coronary artery disease and statins on survival after liver transplantation. Liver Transpl. 2019;25(10):1514-23.
1. Khan SU, Yedlapati SH, Lone AN, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022;4(377):e069116.
1. Jennings DL, Sultan L, Mingov J, Choe J, Latif F, Restaino S, et al. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis. Heart Fail Rev. 2022. https://doi.org/10.1007/s10741-022-10255-5 Online ahead of print.